Gonçalo Cristóvão

Gonçalo Cristóvão

Auto-generated profile, based on publicly available information

Gonçalo Cristóvão

Cardiology Department, Coimbra Hospital and University Centre, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
ASAna Raquel Santiago
Ana Raquel Santiago
Filipa BaptistaFilipa Baptista
Filipa Baptista
Paulo SantosPaulo Santos
Paulo Santos
GCGonçalo Cristóvão
Gonçalo Cristóvão
António Francisco AmbrósioAntónio Francisco Ambrósio
António Francisco Ambrósio
CGCatarina A. Gomes
Catarina A. Gomes
Neuroinflammation mediated by microglial cells in the brain has been commonly associated with neurodegenerative diseases. Whether this microglia-mediated neuroinflammation is cause or consequence of neurodegeneration is still a matter of controversy. However, it is unequivocal that chronic neuroinflammation plays a role in disease progression and halting that process represents a potential therapeutic strategy. The neuromodulator adenosine emerges as a promising targeting candidate based on its ability to regulate microglial proliferation, chemotaxis, and reactivity through the activation of its G protein coupledA2Areceptor (A2AR). This is in striking agreement with the ability ofA2ARblockade to control several brain diseases. Retinal degenerative diseases have been also associated with microglia-mediated neuroinflammation, but the role ofA2ARhas been scarcely explored. This review aims to compare inflammatory features of Parkinson’s and Alzheimer’s diseases with glaucoma and diabetic retinopathy, discussing the therapeutic potential ofA2ARin these degenerative conditions.

4 April 2015 in Glia
Verified
Journal Article
Closed access
PDF file
JGJimmy George
Jimmy George
FGFrancisco Q. Gonçalves
Francisco Q. Gonçalves
GCGonçalo Cristóvão
Gonçalo Cristóvão
LRLisa Rodrigues
Lisa Rodrigues
JFJosé Roberto Meyer Fernandes
José Roberto Meyer Fernandes
CGCatarina A. Gomes
Catarina A. Gomes

2 June 2014 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
GCGonã§Alo Cristovã£O
Gonã§Alo Cristovã£O
MPMaria J. Pinto
Maria J. Pinto
Rodrigo CunhaRodrigo Cunha
Rodrigo Cunha
RARamiro De Almeida
Ramiro De Almeida
CGCatarina A. Gomes
Catarina A. Gomes
Activation of microglia bolsters synapse formation

24 May 2020 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
GCGonçalo Cristóvão
Gonçalo Cristóvão
JMJames Milner
James Milner
PSPedro Sousa
Pedro Sousa
MVMiguel Ventura
Miguel Ventura
JCJoão Cristóvão
João Cristóvão
NANatália António
Natália António
Background: Recent studies suggest that circulating endothelial progenitor cells (EPCs) may influence the response to cardiac resynchronization therapy (CRT). The aim of this study was to evaluate the effect of CRT on EPC levels and to assess the impact of EPCs on long-term clinical outcomes. Population and methods: Prospective study of 50 patients submitted to CRT. Two populations of circulating EPCs were quantified previously to CRT implantation: CD34+KDR+ and CD133+KDR+ cells. EPC levels were reassessed 6 months after CRT. Endpoints during the long-term follow-up were all-cause mortality, heart transplantation, and hospitalization for heart failure (HF) management. Results: The proportion of non-responders to CRT was 42% and tended to be higher in patients with an ischemic vs non-ischemic etiology (64% vs 35%, p = 0.098). Patients with ischemic cardiomyopathy (ICM) showed significantly lower CD34+KDR+ EPC levels when compared to non-ischemic dilated cardiomyopathy patients (DCM) (0.0010 ± 0.0007 vs 0.0030 ± 0.0024 cells/100 leukocytes, p = 0.032). There were no significant differences in baseline EPC levels between survivors and non-survivors nor between patients who were rehospitalized for HF management during follow-up or not. At 6-month follow-up, circulating EPC levels were significantly higher than baseline levels (0.0024 ± 0.0023 vs 0.0047 ± 0.0041 CD34+KDR+ cells/100 leukocytes, p = 0.010 and 0.0007 ± 0.0004 vs 0.0016 vs 0.0013 CD133+/KDR+ cells/100 leukocytes, p = 0.007). Conclusions: Patients with ICM showed significantly lower levels of circulating EPCs when compared to their counterparts. CRT seems to improve the pool of endogenously circulating EPCs and reduced baseline EPC levels seem not to influence long-term outcomes after CRT. Graphical